In particular, ibrutinib, an orally administered Bruton’s tyrosine kinase (BTK) inhibitor, blocks B-cell receptor and chemokine- and cytokine-receptor pathways, thereby affecting survival and expansion of CLL cells [19]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.